| Literature DB >> 33161592 |
Anne E Bras1, Zgjim Osmani1, Valerie de Haas2,3, Mojca Jongen-Lavrencic4, Jeroen G Te Marvelde1, C Michel Zwaan3,5, Ester Mejstrikova6, Paula Fernandez7, Tomasz Szczepanski8, Alberto Orfao9,10, Jacques J M van Dongen11, Vincent H J van der Velden1.
Abstract
Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.Entities:
Keywords: ALL; AML; acute leukaemia; flow cytometry; immunophenotyping; myeloperoxidase
Year: 2020 PMID： 33161592 DOI： 10.1111/bjh.17210
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998